A 62-year-old woman from Mumbai with a history of unopposed estrogen exposure (nulliparity, early menarche, late menopause, obesity, and no prior hormone replacement therapy) presents with postmenopausal bleeding. Endometrial biopsy confirms grade 3 endometrioid adenocarcinoma. Staging investigations reveal tumor confined to the endometrium (no myometrial invasion on MRI), but pelvic and para-aortic lymph nodes are enlarged (short axis >1 cm). Chest CT is normal. What is the most appropriate management strategy?

Explanation

## Clinical Presentation and Risk Assessment **Key Point:** This patient has stage IA (no myometrial invasion) but **grade 3 endometrial cancer** with **radiologically enlarged lymph nodes**, placing her in the **high-risk category** requiring comprehensive surgical staging and aggressive adjuvant therapy. ## Risk Stratification in Endometrial Cancer | Risk Factor | Low Risk | Intermediate Risk | High Risk | |---|---|---|---| | **Grade** | 1–2 | 1–2 | 3 (any histology) | | **Myometrial invasion** | None or <50% | ≥50% or cervical | Any depth | | **Histology** | Endometrioid | Endometrioid | Non-endometrioid, serous, clear cell | | **Lymphovascular invasion** | Absent | Present | Present | | **Age** | <60 years | 60–70 years | >70 years | **High-Yield:** Grade 3 endometrial cancer has significantly higher risk of lymph node metastases (15–25%) and distant recurrence compared to grade 1–2 tumors, regardless of myometrial invasion depth. ## Management Algorithm for High-Risk Early-Stage Endometrial Cancer ```mermaid flowchart TD A[Endometrial Cancer]:::outcome --> B{Grade 3 or non-endometrioid?}:::decision B -->|Yes| C[High-risk disease]:::urgent B -->|No| D[Low/intermediate risk]:::outcome C --> E[Comprehensive surgical staging]:::action E --> F[TAH-BSO + pelvic & para-aortic LND]:::action F --> G{Nodal metastases found?}:::decision G -->|Yes| H[Stage IIIC]:::outcome G -->|No| I[Stage IA-IB]:::outcome H --> J[Chemotherapy ± radiotherapy]:::action I --> K[Chemotherapy ± radiotherapy]:::action ``` ## Rationale for Surgical Staging **Clinical Pearl:** Despite normal imaging, surgical staging is mandatory in grade 3 endometrial cancer because: 1. **High nodal metastasis risk:** Grade 3 tumors have 15–25% risk of pelvic/para-aortic nodal involvement. 2. **Imaging limitations:** MRI and CT have poor sensitivity for detecting small nodal metastases (<1 cm). Enlarged nodes on imaging increase suspicion but do not eliminate the need for histologic confirmation. 3. **Treatment planning:** Nodal status determines whether chemotherapy, radiotherapy, or both are indicated. 4. **Prognostic value:** Complete staging provides accurate prognostic information. **Key Point:** The presence of radiologically enlarged lymph nodes in this case actually strengthens the indication for comprehensive surgical staging with lymphadenectomy, as these nodes may harbor metastatic disease. ## Adjuvant Therapy for High-Risk Disease **High-Yield:** Grade 3 endometrial cancer with or without nodal metastases typically requires adjuvant therapy: - **Chemotherapy:** Carboplatin and paclitaxel (TC) is the standard regimen for high-risk endometrial cancer. - **Radiotherapy:** Pelvic external beam radiotherapy (EBRT) ± brachytherapy may be added depending on extent of disease and nodal involvement. - **Combined modality:** Chemotherapy followed by radiotherapy is often used for stage IIIC (nodal metastases) disease. **Mnemonic:** **CHEMO-RAD** — **C**hemotherapy (carboplatin-paclitaxel) followed by **H**igh-dose radiotherapy in high-risk endometrial cancer. ## Why Immediate Surgery Is Preferred Over Neoadjuvant Chemotherapy 1. **Accurate staging:** Surgery provides definitive nodal staging, which guides adjuvant therapy decisions. 2. **Prognostic information:** Pathologic findings determine intensity of adjuvant therapy. 3. **Standard practice:** Upfront surgery followed by adjuvant therapy is the established paradigm for operable early-stage high-risk endometrial cancer. 4. **Neoadjuvant chemotherapy:** Reserved for advanced/unresectable disease or when surgery is not feasible. [cite:Berek & Hacker's Gynecologic Oncology 6e Ch 8; NCCN Uterine Neoplasms Guidelines 2023]